Tempus AI (F3M) Stock Overview
Operates as a healthcare technology company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
F3M Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Tempus AI, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$66.70 |
| 52 Week High | US$71.00 |
| 52 Week Low | US$35.85 |
| Beta | 3.72 |
| 1 Month Change | 11.89% |
| 3 Month Change | 63.82% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 46.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| F3M | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 29.5% | 6.9% | -0.6% |
| 1Y | n/a | 7.7% | 4.0% |
Return vs Industry: Insufficient data to determine how F3M performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how F3M performed against the German Market.
Price Volatility
| F3M volatility | |
|---|---|
| F3M Average Weekly Movement | 12.7% |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: F3M's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine F3M's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3,800 | Eric Lefkofsky | www.tempus.com |
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.
Tempus AI, Inc. Fundamentals Summary
| F3M fundamental statistics | |
|---|---|
| Market cap | €12.23b |
| Earnings (TTM) | -€221.50m |
| Revenue (TTM) | €1.25b |
Is F3M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| F3M income statement (TTM) | |
|---|---|
| Revenue | US$1.43b |
| Cost of Revenue | US$515.83m |
| Gross Profit | US$916.19m |
| Other Expenses | US$1.17b |
| Earnings | -US$254.42m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.41 |
| Gross Margin | 63.98% |
| Net Profit Margin | -17.77% |
| Debt/Equity Ratio | 305.8% |
How did F3M perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 08:04 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tempus AI, Inc. is covered by 28 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |
| Michael Ryskin | BofA Global Research |